相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。The unique characteristics of tumor vasculature and preclinical evidence for its selective disruption by Tumor-Vascular Disrupting Agents
Dietmar W. Siemann
CANCER TREATMENT REVIEWS (2011)
Discovery of a potent tubulin polymerization inhibitor: Synthesis and evaluation of water-soluble prodrugs of benzophenone analog
Jaekwang Lee et al.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS (2010)
Leukemia regression by vascular disruption and antiangiogenic therapy
Gerard J. Madlambayan et al.
BLOOD (2010)
Phase I trial of CYT997, a novel cytotoxic and vascular-disrupting agent
J. D. Lickliter et al.
BRITISH JOURNAL OF CANCER (2010)
Disrupting Established Tumor Blood Vessels An Emerging Therapeutic Strategy for Cancer
Mark J. McKeage et al.
CANCER (2010)
Tumor vasculature as target for therapeutic intervention
Marcel H. A. M. Fens et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2010)
Combretastatin A4 phosphate: a novel vascular disrupting agent
Govardhanan Nagaiah et al.
FUTURE ONCOLOGY (2010)
Tumor Vascularization in Cervical Cancer by 3-Dimensional Power Doppler Angiography Correlation With Tumor Characteristics
Juan Luis Alcazar et al.
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER (2010)
A dose escalation, safety, and tolerability study of MN-029 in patients with advanced solid tumors
Anne M. Traynor et al.
INVESTIGATIONAL NEW DRUGS (2010)
Quantitative MR in Multi-center Clinical Trials
Edward Ashton
JOURNAL OF MAGNETIC RESONANCE IMAGING (2010)
Identification of CKD-516: A Potent Tubulin Polymerization Inhibitor with Marked Antitumor Activity against Murine and Human Solid Tumors
Jaekwang Lee et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Three-dimensional analysis of tumour vascular corrosion casts using stereoimaging and micro-computed tomography
A. A. Folarin et al.
MICROVASCULAR RESEARCH (2010)
BNC105: A Novel Tubulin Polymerization Inhibitor That Selectively Disrupts Tumor Vasculature and Displays Single-Agent Antitumor Efficacy
Gabriel Kremmidiotis et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Going deeper than microscopy: the optical imaging frontier in biology
Vasilis Ntziachristos
NATURE METHODS (2010)
Intrinsic Susceptibility MR Imaging of Chemically Induced Rat Mammary Tumors: Relationship to Histologic Assessment of Hypoxia and Fibrosis
Lesley D. McPhail et al.
RADIOLOGY (2010)
Can Vascularity at Power Doppler US Help Predict Thyroid Malignancy?
Hee Jung Moon et al.
RADIOLOGY (2010)
Multiparametric Imaging of Tumor Response to Therapy
Anwar R. Padhani et al.
RADIOLOGY (2010)
Vascular Disrupting Agents (VDAs) in Anticancer Therapy
Laura G. M. Daenen et al.
CURRENT CLINICAL PHARMACOLOGY (2010)
Discovery of 4-Aryl-4H-Chromenes as Potent Apoptosis Inducers Using a Cell- and Caspase-Based Anti-Cancer Screening Apoptosis Program (ASAP): SAR Studies and the Identification of Novel Vascular Disrupting Agents
Sui Xiong Cai et al.
ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY (2009)
ABT-751, a novel tubulin-binding agent, decreases tumor perfusion and disrupts tumor vasculature
Yanping Luo et al.
ANTI-CANCER DRUGS (2009)
Why are tumour blood vessels abnormal and why is it important to know?
J. A. Nagy et al.
BRITISH JOURNAL OF CANCER (2009)
Contribution of Granulocyte Colony-Stimulating Factor to the Acute Mobilization of Endothelial Precursor Cells by Vascular Disrupting Agents
Yuval Shaked et al.
CANCER RESEARCH (2009)
Beyond RECIST: Molecular and functional imaging techniques for evaluation of response to targeted therapy
I. M. E. Desar et al.
CANCER TREATMENT REVIEWS (2009)
Vascular targeted therapies in oncology
Dietmar W. Siemann et al.
CELL AND TISSUE RESEARCH (2009)
Antivascular Actions of Microtubule-Binding Drugs
Edward L. Schwartz
CLINICAL CANCER RESEARCH (2009)
A review and update of the current status of the vasculature-disabling agent combretastatin-A4 phosphate (CA4P)
Dietmar W. Siemann et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
AVE8062: a new combretastatin derivative vascular disrupting agent
Angelo Delmonte et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
Microtubule depolymerizing vascular disrupting agents: novel therapeutic agents for oncology and other pathologies
Chryso Kanthou et al.
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY (2009)
MRI-based characterization of vascular disruption by 5,6-dimethylxanthenone-acetic acid in gliomas
Mukund Seshadri et al.
JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM (2009)
Tubulin-Interactive Natural Products as Anticancer Agents
David G. I. Kingston
JOURNAL OF NATURAL PRODUCTS (2009)
Simultaneous 3D Visualization and Quantification of Murine Bone and Bone Vasculature Using Micro-Computed Tomography and Vascular Replica
Philipp Schneider et al.
MICROSCOPY RESEARCH AND TECHNIQUE (2009)
Blood flow and Vd (water): both biomarkers required for interpreting the effects of vascular targeting agents on tumor and normal tissue
Barbara Koetz et al.
MOLECULAR CANCER THERAPEUTICS (2009)
CYT997: a novel orally active tubulin polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivo
Christopher J. Burns et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models
Laura G. Daenen et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Three-Compartment T1 Relaxation Model for Intracellular Paramagnetic Contrast Agents
Gustav J. Strijkers et al.
MAGNETIC RESONANCE IN MEDICINE (2009)
Rapid Monitoring of Oxygenation by 19F Magnetic Resonance Imaging: Simultaneous Comparison with Fluorescence Quenching
Benedicte F. Jordan et al.
MAGNETIC RESONANCE IN MEDICINE (2009)
Anticancer strategies involving the vasculature
Victoria L. Heath et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2009)
Model-based and model-free parametric analysis of breast dynamic-contrast-enhanced MRI
Evez Eyal et al.
NMR IN BIOMEDICINE (2009)
Vascular Disrupting Agents: A Novel Mechanism of Action in the Battle Against Non-Small Cell Lung Cancer
Cesare Gridelli et al.
ONCOLOGIST (2009)
Assessment of endometrial and ovarian characteristics using three dimensional power Doppler ultrasound to predict response in frozen embryo transfer cycles
Tamara Zackova et al.
REPRODUCTIVE BIOLOGY AND ENDOCRINOLOGY (2009)
DETECTABILITY OF SMALL BLOOD VESSELS WITH HIGH-FREQUENCY POWER DOPPLER AND SELECTION OF WALL FILTER CUT-OFF VELOCITY FOR MICROVASCULAR IMAGING
Stephen Z. Pinter et al.
ULTRASOUND IN MEDICINE AND BIOLOGY (2009)
Molecular Ultrasound Imaging of Early Vascular Response in Prostate Tumors Irradiated with Carbon Ions
Moritz Palmowski et al.
NEOPLASIA (2009)
Tumour vascular disrupting agents: combating treatment resistance
G. M. Tozer et al.
BRITISH JOURNAL OF RADIOLOGY (2008)
The pervasive presence of fluctuating oxygenation in tumors
Laura I. Cardenas-Navia et al.
CANCER RESEARCH (2008)
Colchicine Site Inhibitors of Microtubule Integrity as Vascular Disrupting Agents
Ray M. Lee et al.
DRUG DEVELOPMENT RESEARCH (2008)
Dynamic bioluminescence imaging for quantitative tumour burden assessment using IV or IP administration of D-luciferin: effect on intensity, time kinetics and repeatability of photon emission
Marleen Keyaerts et al.
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING (2008)
Antivascular effects of combretastatin A4 phosphate in breast cancer xenograft assessed using dynamic bioluminescence imaging and confirmed by MRI
Dawen Zhao et al.
FASEB JOURNAL (2008)
Vessel size index magnetic resonance imaging to monitor the effect of antivascular treatment in a rodent tumor model
Franklyn A. Howe et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2008)
A phase II study of ABT-751 in patients with advanced non-small cell lung cancer
Ann M. Mauer et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Paracingulin Regulates the Activity of Rac1 and RhoA GTPases by Recruiting Tiam1 and GEF-H1 to Epithelial Junctions
Laurent Guillemot et al.
MOLECULAR BIOLOGY OF THE CELL (2008)
Incorporating the effects of transcytolemmal water exchange in a reference region model for DCE-MRI analysis: Theory, simulations, and experimental results
Thomas E. Yankeelov et al.
MAGNETIC RESONANCE IN MEDICINE (2008)
Novel three-dimensional analysis tool for vascular trees indicates complete micro-networks, not single capillaries, as the angiogenic endpoint in mice overexpressing human VEGF165 in the brain
Stefan Heinzer et al.
NEUROIMAGE (2008)
Nephrogenic systemic fibrosis: A chemical perspective
Neil M. Rofsky et al.
RADIOLOGY (2008)
Cellular functions of GEF-H1, a microtubule-regulated Rho-GEF: is altered GEF-H1 activity a crucial determinant of disease pathogenesis?
Joerg Birkenfeld et al.
TRENDS IN CELL BIOLOGY (2008)
Multiple reference tissue method for contrast agent arterial input function estimation
Cheng Yang et al.
MAGNETIC RESONANCE IN MEDICINE (2007)
Assessment of tumor response to the vascular disrupting agents 5,6-dimethylxanthenone-4-acetic acid or combretastatin-a4-phosphate by intrinsic susceptibility magnetic resonance imaging
Lesley D. Mcphail et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
Simultaneous dynamic T1 and T*2 measurement for AIF assessment combined with DCE MRI in a mouse tumor model
Melanie Heilmann et al.
MAGNETIC RESONANCE MATERIALS IN PHYSICS BIOLOGY AND MEDICINE (2007)
MPC-6827: A small-molecule inhibitor of microtubule formation that is not a substrate for multidrug resistance pumps
Shailaja Kasibhatla et al.
CANCER RESEARCH (2007)
Vascular disrupting agents in clinical development
P. Hinnen et al.
BRITISH JOURNAL OF CANCER (2007)
Tumor antivascular effects of radiotherapy combined with combretastatin A4 phosphate in human non-small-cell lung cancer
Quan-Sing Ng et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2007)
Three-dimensional culture models of normal and malignant breast epithelial cells
Genee Y. Lee et al.
NATURE METHODS (2007)
Early effects of combretastatin-A4 disodium phosphate on tumor perfusion and interstitial fluid pressure
Carsten D. Ley et al.
NEOPLASIA (2007)
Small molecule vascular disrupting agents: Potential new drugs for cancer treatment
Sui X. Cai
RECENT PATENTS ON ANTI-CANCER DRUG DISCOVERY (2007)
FDA drug approval summary: Bevacizumab (Avastin (R)) plus carboplatin and paclitaxel as first-line treatment of advanced/metastatic recurrent nonsquamous non-small cell lung cancer
Martin H. Cohen et al.
ONCOLOGIST (2007)
Pathophysiologic effects of vascular-targeting agents and the implications for combination with conventional therapies
Michael R. Horsman et al.
CANCER RESEARCH (2006)
Vascular disrupting agents
M. J. Pilat et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2006)
Characterizing vascular parameters in hypoxic regions: A combined magnetic resonance and optical imaging study of a human prostate cancer model
Venu Raman et al.
CANCER RESEARCH (2006)
Early effects of combretastatin A4 phosphate assessed by anatomic and carbogen-based functional magnetic resonance imaging on rat bladder tumors implanted in nude mice
Carole D. Thomas et al.
NEOPLASIA (2006)
Effect of the second-generation vascular disrupting agent OXi4503 on tumor vascularity
Howard W. Salmon et al.
CLINICAL CANCER RESEARCH (2006)
Design, synthesis, and biological evaluation of combretastatin nitrogen-containing derivatives as inhibitors of tubulin assembly and vascular disrupting agents
KA Monk et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2006)
The effects of the vascular disrupting agents combretastatin A-4 disodium phosphate, 5,6-dimethylxanthenone-4-acetic acid and ZD6126 in a murine tumour: A comparative assessment using MRI and MRS
T Breidahl et al.
ACTA ONCOLOGICA (2006)
5,6-Dimethylxanthenone-4-acetic acid in the treatment of refractory tumors: a phase I safety study of a vascular disrupting agent
M McKeage et al.
CLINICAL CANCER RESEARCH (2006)
GEF-H1 is involved in agonist-induced human pulmonary endothelial barrier dysfunction
AA Birukova et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2006)
Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis
Lesley D. McPhail et al.
NEOPLASIA (2006)
Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers
MR Dreher et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2006)
New polyurethane-based material for vascular corrosion casting with improved physical and imaging characteristics
T Krucker et al.
MICROSCOPY RESEARCH AND TECHNIQUE (2006)
NPI-2358 is a tubulin-depolymerizing agent: in-vitro evidence for activity as a tumor vascular-disrupting agent
B Nicholson et al.
ANTI-CANCER DRUGS (2006)
Endothelial extracellular matrix - Biosynthesis, remodeling, and functions during vascular morphogenesis and neovessel stabilization
GE Davis et al.
CIRCULATION RESEARCH (2005)
Angiogenesis inhibitors in the treatment of cancer
J Rhee et al.
EXPERT OPINION ON PHARMACOTHERAPY (2005)
Bioluminescent imaging of TRAIL-induced apoptosis through detection of caspase activation following cleavage of DEVD-aminoluciferin
JJ Liu et al.
CANCER BIOLOGY & THERAPY (2005)
Bevacizumab (Avastin), a humanized anti-VEGF monoclonal antibody for cancer therapy
N Ferrara et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2005)
Tumor physiologic response to combretastatin A4 phosphate assessed by MRI
DW Zhao et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2005)
Continuous low-dose (metronomic) chemotherapy on rat prostate tumors evaluated using MRI in vivo and comparison with histology
DW Zhao et al.
NEOPLASIA (2005)
Effect of intravascular-to-extravascular water exchange on the determination of blood-to-tissue transfer constant by magnetic resonance Imaging
Y Cao et al.
MAGNETIC RESONANCE IN MEDICINE (2005)
Universal use of nonionic lodinated contrast medium for CT: Evaluation of safety in a large urban teaching hospital
KJ Mortele et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2005)
Validating Bioluminescence Imaging as a High-Throughput, Quantitative Modality for Assessing Tumor Burden
Zain Paroo et al.
MOLECULAR IMAGING (2004)
Single dose of the antivascular agent, ZD6126 (N-acetylcoichinol-O-phosphate), reduces perfusion for at least 96 hours in the GH3 prolactinoma rat tumor model
DJO McIntyre et al.
NEOPLASIA (2004)
Vascular targeting agents as cancer therapeutics
PE Thorpe
CLINICAL CANCER RESEARCH (2004)
Tumor reversion: Correction of malignant behavior by microenvironmental cues
PA Kenny et al.
INTERNATIONAL JOURNAL OF CANCER (2003)
Combretastatin A4 phosphate has tumor antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging
SM Galbraith et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging
SP Robinson et al.
BRITISH JOURNAL OF CANCER (2003)
Functional tumor imaging with dynamic contrast-enhanced magnetic resonance imaging
PL Choyke et al.
JOURNAL OF MAGNETIC RESONANCE IMAGING (2003)
Tumor vascular architecture and function evaluated by non-invasive susceptibility MRI methods and immunohistochemistry
SP Robinson et al.
JOURNAL OF MAGNETIC RESONANCE IMAGING (2003)
Phase I trial of the antivascular agent combretastatin A4 phosphate on a 5-day schedule to patients with cancer: Magnetic resonance imaging evidence for altered tumor blood flow
JP Stevenson et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Evaluation of antimitotic agents by quantitative comparisons of their effects on the polymerization of purified tubulin
E Hamel
CELL BIOCHEMISTRY AND BIOPHYSICS (2003)
MRI for assessing antivascular cancer treatments
AR Padhani
BRITISH JOURNAL OF RADIOLOGY (2003)
Regulation of microvascular permeability by vascular endothelial growth factors
DO Bates et al.
JOURNAL OF ANATOMY (2002)
Enhancement of radiation therapy by the novel vascular targeting agent ZD6126
DW Siemann et al.
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2002)
Assessment of protamine-induced thrombosis of tumor vessels for cancer therapy using dynamic contrast-enhanced MRI
MY Su et al.
NMR IN BIOMEDICINE (2002)
Differential sensitivity of two adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-dimethylxanthenone-4-acetic acid, assessed using MRI and MRS
DA Beauregard et al.
NMR IN BIOMEDICINE (2002)
Evaluation of the anti-vascular effects of combretastatin in rodent tumours by dynamic contrast enhanced MRI
RJ Maxwell et al.
NMR IN BIOMEDICINE (2002)
Nucleotide exchange factor GEF-H1 mediates cross-talk between microtubules and the actin cytoskeleton
M Krendel et al.
NATURE CELL BIOLOGY (2002)
VEGF increases permeability of the endothelial cell monolayer by activation of PKB/akt, endothelial nitric-oxide synthase, and MAP kinase pathways
BK Lal et al.
MICROVASCULAR RESEARCH (2001)
Issues in flow and oxygenation dependent contrast (FLOOD) imaging of tumours
FA Howe et al.
NMR IN BIOMEDICINE (2001)
Interaction between combretastatin A-4 disodium phosphate and radiation in murine tumors
R Murata et al.
RADIOTHERAPY AND ONCOLOGY (2001)
3D microvascular architecture of pre-cancerous lesions and invasive carcinomas of the colon
MA Konerding et al.
BRITISH JOURNAL OF CANCER (2001)
Monoclonal antibodies directed to different regions of vascular endothelial cadherin extracellular domain affect adhesion and clustering of the protein and modulate endothelial permeability
M Corada et al.
BLOOD (2001)
Gene expression profiling of exposure to TZT-1027, a novel microtubule-interfering agent, in non-small cell lung cancer PC-14 cells and astrocytes
T Natsume et al.
INVESTIGATIONAL NEW DRUGS (2001)
Noninvasive investigation of blood oxygenation dynamics of tumors by near-infrared spectroscopy
HL Liu et al.
APPLIED OPTICS (2000)
The influence of the microenvironment on the malignant phenotype
CC Park et al.
MOLECULAR MEDICINE TODAY (2000)
分享论文
